Testing a new eye injection for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This study tests an experimental drug, EXG202, injected into the eye to treat wet age-related macular degeneration (wAMD). It is for people who have already had some benefit from standard treatments in the past 6 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years or older.
- You must have wet AMD with active signs like fluid or bleeding in the back of the eye.
- Your vision in the study eye should be between 20/40 and 20/400 on an eye chart.
- You must have had a positive response to standard anti-VEGF treatment in the past 6 months.
- You must not have other eye diseases that affect central vision, like a macular hole.
- You must agree to use effective birth control if you could become pregnant or get someone pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy, EXG202, given as an injection into the eye. It aims to see if the treatment is safe and can help slow vision loss from wet AMD, a condition where abnormal blood vessels leak fluid under the retina.
This trial tests an investigational eye injection called AL-001 for people with wet age-related macular degeneration (AMD) that has responded to previous anti-VEGF treatment. The goal is to see if it improves vision and is safe.
This study checks on the long-term safety and effects of a one-time treatment (EXG102-031) for wet age-related macular degeneration. It is only for people who already received that treatment in a previous study.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This trial tests a new CRISPR-based treatment for wet age-related macular degeneration (AMD). It aims to stop vision loss by targeting the cause of abnormal blood vessel growth in the eye. This study is for people who have already tried anti-VEGF injections but might not be responding well enough.
Hear when a new Wet Age-related Macular Degeneration (wAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.